Financial Performance - The company's revenue for Q3 2025 reached ¥2,564,308,490.01, representing a year-on-year increase of 13.48%[4] - Net profit attributable to shareholders was ¥72,896,120.41, a significant increase of 294.98% compared to the same period last year[4] - The basic earnings per share rose to ¥0.18, marking a 300.00% increase year-on-year[4] - In the first three quarters of 2025, the company achieved operating revenue of CNY 744.55 million, a year-on-year increase of 5.19%, and a net profit attributable to shareholders of CNY 109.15 million, a significant increase of 927.37%[19] - The net profit excluding non-recurring gains and losses reached CNY 9.40 million, up 160.23% year-on-year[19] - Net profit for the period was ¥100,856,450.25, a significant recovery from a net loss of ¥28,498,927.90 in the previous year[35] - Operating profit improved to ¥147,147,406.05 compared to a loss of ¥1,623,384.50 in the same period last year[33] - Basic and diluted earnings per share were both ¥0.27, recovering from a loss of ¥0.03 per share in the previous year[36] - The company reported a total profit of ¥135,578,418.79, recovering from a loss of ¥16,285,037.28 in the same period last year[35] Assets and Liabilities - The total assets of the company increased to ¥10,018,705,946.99, reflecting an 8.04% growth from the previous year[7] - The company's goodwill increased by 30.21% to ¥2,281,932,857.80, primarily due to acquisitions during the reporting period[12] - The company’s liabilities increased, with accounts payable rising by 51.48% to ¥1,751,998,626.26, indicating higher purchase obligations[12] - The total current liabilities rose to ¥6,189,778,365.92 from ¥5,362,410,305.97, marking an increase of approximately 15.4%[30] - The total non-current liabilities decreased to ¥1,598,619,358.35 from ¥1,785,712,083.01, reflecting a decline of about 10.5%[31] - The company's total equity increased to ¥2,230,308,222.72 from ¥2,125,070,292.99, indicating a growth of approximately 4.9%[31] Cash Flow and Investments - The company reported a net cash flow from operating activities of ¥624,163,644.07, which is a 160.56% increase year-to-date[4] - Cash flow from operating activities generated a net inflow of ¥624,163,644.07, up from ¥239,543,017.67 in the prior year[38] - Investment activities resulted in a net cash outflow of ¥728,805,481.89, worsening from a smaller outflow of ¥21,901,815.19 in the previous year[38] Operational Metrics - The overall gross margin declined by 1.35% due to changes in industry policies, regulatory environments, and consumer behavior[20] - The company optimized its store network, resulting in a year-on-year improvement in the expense-to-sales ratio by 1.45%[20] - As of September 30, 2025, the company operated a total of 8,617 stores across several provinces, with 4,972 being direct-operated stores[21] - The company has a steady expansion strategy, having opened 3 new stores and acquired 754 stores while closing 223 stores in the reporting period[21] - A total of 1,939 convertible bonds were converted into 12,832 shares of stock by the end of September 2025[22] - The company continues to focus on a direct chain marketing model and regional deep cultivation strategies to enhance profitability[21] Market and Product Development - The company is diversifying its product offerings to include health products, healthcare items, medical devices, and beauty products to meet consumer demand[21] - The company reported a revenue increase of 15% year-over-year, reaching 1.2 billion RMB in Q3 2025[41] - User data showed a growth of 20% in active customers, totaling 5 million users by the end of Q3 2025[41] - New product launches contributed to a 25% increase in sales in the health supplement category[41] - The company is investing 50 million RMB in R&D for new technology aimed at improving customer experience[41] - Market expansion efforts have led to the opening of 30 new stores in tier-2 cities, increasing the total store count to 200[41] - The company is exploring potential acquisitions to enhance its product offerings and market presence[41] - A new marketing strategy is projected to increase brand awareness by 15% in the next quarter[41] - The gross margin improved to 35%, up from 32% in the previous quarter[41] - The company plans to allocate 10% of its revenue towards sustainability initiatives in the upcoming fiscal year[41] Other Financial Metrics - The company confirmed a fair value change gain of ¥127,905,105.59, a dramatic increase of 196,527.69% compared to the previous period[12] - The company's cash and cash equivalents decreased to ¥1,306,337,761.38 from ¥1,404,760,376.62, representing a decline of approximately 7.0%[27] - Inventory levels increased to ¥2,099,057,605.58 from ¥1,891,086,015.63, showing a rise of about 11.0%[28] - The company incurred a tax expense of ¥34,721,968.54, compared to ¥12,213,890.62 in the previous year, indicating a rise in tax obligations[35] - Total operating costs increased to ¥7,426,697,847.88 from ¥7,068,782,768.84, representing a rise of approximately 5.06% year-over-year[33] - The company decided not to adjust the conversion price of the "Shuyu Convertible Bonds" despite triggering conditions for downward adjustment, maintaining the price at ¥12.71 per share[25] - The company will reassess the conversion price adjustment rights if the conditions are triggered again after December 9, 2025[25]

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-090 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 2025 年第四次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会不存在变更、否决提案的情况； 2、本次股东大会不涉及变更前次股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开情况 （1）会议召开时间、地点及召开方式 漱玉平民大药房连锁股份有限公司（以下简称"公司"）2025 年第四次临时股东大会 于 2025 年 10 月 27 日下午 2:30 在山东省济南市历城区山大北路 56 号公司会议室以现场表 决和网络投票相结合的方式召开。通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 10 月 27 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投 票系统进行投票的具体时间为 2025 年 10 月 27 日 9:15-15 ...

北京德恒（济南）律师事务所 关于漱玉平民大药房连锁股份有限公司 2025 年第四次临时股东大会的 法律意见 关于漱玉平民大药房连锁股份有限公司 2025 年第四次临时股东大会的 法律意见 德恒 11G20230145-15 号 致：漱玉平民大药房连锁股份有限公司 地址：山东省济南市高新区舜泰北路 567 号银丰科技公园 2 号楼 邮编：250102 网址：www.dehenglaw.com 电话：（86）531-8166 3606 北京德恒（济南）律师事务所 关于漱玉平民大药房连锁股份有限公司 2025 年第四次临时股东大会的法律意见 北京德恒（济南）律师事务所 北京德恒（济南）律师事务所（以下简称"本所"）作为漱玉平民大药房连 锁股份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派段振 波律师、赵程程律师（以下简称"本所律师"）出席公司 2025 年第四次临时股 东大会（以下简称"本次股东大会"），依据《中华人民共和国公司法》（以下 简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规则》）等现 行有效的法律、法规、规范性文件以及《漱玉平民大药房连锁股份有限公司章程》 （以下简称《公司章 ...

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-089 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日召开第 四届董事会第三次会议，于 2025 年 2 月 6 日召开 2025 年第一次临时股东大会，审议通过 了《关于 2025 年度公司及子公司向银行等机构申请综合授信额度及提供担保的议案》，同 意公司及子公司 2025 年度对合并报表范围内各级子公司提供的担保额度为人民币 167,011.00 万元。其中公司向控股子公司福建省民心医药连锁有限公司（以下简称"福建 民心"）提供不超过 1,800 万元的担保额度。担保额度有效期自 2025 年第一次临时股东大 会审议通过之日起十二个月。具体内容详见公司于 2025 年 1 月 22 日和 2025 年 2 月 ...

Core Viewpoint - The company, Shuyupingmin, experienced a slight decline in stock price and notable changes in financing activities, indicating a mixed sentiment among investors [1][2]. Financing Activities - On October 16, Shuyupingmin's stock price fell by 0.63%, with a trading volume of 31.01 million yuan [1]. - The financing buy-in amount for the day was 1.347 million yuan, while the financing repayment was 3.6138 million yuan, resulting in a net financing outflow of 2.2668 million yuan [1]. - As of October 16, the total financing and securities lending balance was 69.745 million yuan, which represents 1.57% of the circulating market value, indicating a high level compared to the past year [1]. Securities Lending - On the same day, there were no shares sold or repaid in securities lending, with a remaining balance of 0 shares and 0 yuan, placing it in the 80th percentile of the past year's data, indicating a high level [1]. Company Overview - Shuyupingmin is a retail pharmacy chain based in Jinan, Shandong Province, established on January 21, 1999, and listed on July 5, 2021 [1]. - The company's main business involves pharmaceutical retail, with 99.03% of revenue coming from traditional Chinese and Western medicines, and 0.97% from other supplementary products [1]. Financial Performance - For the first half of 2025, Shuyupingmin reported a revenue of 4.881 billion yuan, reflecting a year-on-year growth of 1.30% [2]. - The net profit attributable to shareholders was 36.2509 million yuan, showing a significant year-on-year increase of 49.83% [2]. - Since its A-share listing, the company has distributed a total of 141 million yuan in dividends, with 66.7317 million yuan paid out over the last three years [2]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 7.36% to 14,100, while the average circulating shares per person decreased by 6.86% to 17,259 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the eighth largest, holding 1.2625 million shares as a new shareholder [2].

（文章来源：证券日报） 证券日报网讯 10月16日晚间，漱玉平民发布公告称，东兴证券作为公司向不特定对象发行可转换公司 债券项目的保荐机构，目前正在履行持续督导职责。东兴证券原委派周磊先生、胡杰畏先生作为公司保 荐代表人，负责上述项目的持续督导工作。公司向不特定对象发行可转换公司债券项目的持续督导期至 2025年12月31日止。因原委派保荐代表人周磊先生工作变动，为保证持续督导工作的有序进行，现东兴 证券委派保荐代表人邹成凤先生接替周磊先生负责项目后续的持续督导工作，继续履行持续督导职责。 ...

| | | 漱玉平民大药房连锁股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于近日收到东兴证券股份有限 公司（以下简称"东兴证券"）出具的《关于更换持续督导保荐代表人的函》，具体情况如 下： 东兴证券作为公司向不特定对象发行可转换公司债券项目的保荐机构，目前正在履行 持续督导职责。东兴证券原委派周磊先生、胡杰畏先生作为公司保荐代表人，负责上述项 目的持续督导工作。公司向不特定对象发行可转换公司债券项目的持续督导期至 2025 年 12 月 31 日止。 因原委派保荐代表人周磊先生工作变动，为保证持续督导工作的有序进行，现东兴证 券委派保荐代表人邹成凤先生接替周磊先生负责项目后续的持续督导工作，继续履行持续 督导职责。 本次变更后，负责公司向不特定对象发行可转换公司债券项目持续督导工作的保荐代 表人为邹成凤先生、胡杰畏先生。持续督导期限直至持续督导义务结束为止。 公司董事会对周磊先生在担任公司保荐代表人期间所作的贡献表示衷心的感谢。 特此公告。 漱玉平民大药房连 ...

Group 1 - The controlling shareholder and chairman of Shuyupingmin, Li Wenjie, reduced his stake by 2 million shares through block trading, accounting for 0.49% of the company's total share capital [1] - Li Wenjie plans to further reduce his holdings by up to 8.0473 million shares through block trading between August 28, 2025, and November 27, 2025 [1] - Following the reduction, the combined shareholding of Li Wenjie and his concerted parties decreased from 54.08% to 53.59% [1]